TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CKD patients with type 2 diabetes mellitus~* Patients whose estimated GFR levels are eligible for this study~* Patients being treated with stable dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin II receptor blocker (ARB) etc.~Exclusion Criteria:~* Patients with type 1 diabetes mellitus~* Patients with known non-diabetic renal disease~* Patients with a history of renal transplantation~* Patients with mean systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 90 mmHg~* Patients with Hemoglobin A1c \> 10%~* Patients with cardiovascular disease specified in the study protocol etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- bardoxolone methyl (Type: EXPERIMENTAL): bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, once daily for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Identification of Myocardial Impairment in PBC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for PBC group:~* Age between 18-80 years old.~* Definite primary biliary cirrhosis diagnosis which is consistent with European Association for the Study of the Liver (EASL) \[Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis (2017)\]. The following three diagnostic factors, at least meet two:~  1. History of elevated alkaline phosphatase (ALP) levels;~ 2. Liver biopsy consistent with PBC;~ 3. Positive antimitochondrial antibodies (AMA) or specific antinuclear antibodies;~* Providing written informed consent~Exclusion Criteria:~* History or presence of other concomitant liver disease including:~  1. cirrhosis or viral hepatitis;~ 2. Inherited metabolic liver disease;~ 3. Drug-induced liver injury;~ 4. Other systemic disease inducing liver change.~* Subjects with life expectancy \< 6 months.~* Subjects with known ischemic/non-ischemic cardiomyopathy or abnormal in cardiac-related examinations.~* Subjects with standard metallic contraindications to CMR (i.e., estimated glomerular filtration rate \< 30 ml/min/1.73 m2, New York Heart Association functional capacity class IV)~Inclusion Criteria for Control group:~* Absence of known systemic diseases~* Normal examinations in CMR/Echo/ECG~* Age between 18-80 years old.~* Providing written informed consent~Exclusion Criteria:~* Subjects with known heart disease including:~  1. Documented coronary artery disease;~ 2. Ischemia/non-ischemia cardiomyopathy;~ 3. Other systemic disease inducing heart change.~* Subjects with known liver disease including:~  1. Viral hepatitis;~ 2. Inherited metabolic liver disease;~ 3. Drug-induced liver injury;~ 4. Other systemic disease inducing liver change.~* Subjects with standard metallic contraindications to CMR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- PBC group (Type: None): Patients have a definite PBC diagnosis.
- Control group (Type: None): The healthy volunteers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hand Dysfunction After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2-24 weeks after stroke~* Greater than 21 years old~* Ability to follow 2 step commands~Exclusion Criteria:~* Chronic, progressive medical condition (i.e. Parkinson's Disease)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FES and Motor Learning Training (Type: EXPERIMENTAL): participants \<6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
- Control group (Type: OTHER): Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as having endometriosis by laparotomy or laparoscopy, or by identification of chocolate cyst of endometriosis, or patients with the clinical diagnosis of endometriosis, who fulfill the condition of pelvic tenderness or induration of Cul-de-sac or uterine immobility~* Patient with pelvic pain judged by the highest Visual Analogue Scale (VAS) value of 40 mm or higher which is determined during 2 menstrual cycles before randomization (baseline observation phase)~* Patients having the normal menstrual cycle (25 to 38 days) in the latest two menses before randomization (baseline observation phase)~* Patients who do not wish to become pregnant during the course of the study~Exclusion Criteria:~* Patients who have organic diseases of which surgical treatment is prioritized by investigator~* Patients in whom any hormonal therapies, including combined oral contraceptives (COCs) and progestins, have failed for treatment of symptomatic endometriosis (moderate, severe pain)~* Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese Labeling)~* Patients for whom dienogest is contraindicated (according to Japanese labeling of Dinagest Tab 1mg)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 50-85 years old~* Able to walk for 6 minutes~* Diabetes type 2 (DM) group: diagnosis and treatment for type 2 DM with non-insulin oral or injectable agents~* Non-DM group with similar age range as the DM group, non-diabetic fasting plasma glucose (\<126 mg/dL) and hemoglobin A1c (HbA1c) (\<6.5%)~* Participants capable of providing informed consent~Exclusion Criteria:~* Type 2 DM treated with insulin (since 9/25/2017)~* Type 1 DM~* Intolerance to insulin~* History of severe hypoglycemia~* Participants who have \>1 asymptomatic and/or symptomatic episode of hypoglycemia (glucose \< 54 mg/dL) during finger stick or plasma glucose (cut off value since 6/11/2018)~* Acute medical condition that required either hospitalization or surgery within the past 6 months (e.g., severe hypoglycemia, malignancies, myocardial infarction,stroke)~* Liver or renal failure or transplant~* Dementia (Mini Mental State Examination \[MMSE\] scores ≤20)~* Current recreational drug or alcohol abuse~* Serious systemic disease that would interfere with conduction of clinical trial (mild forms of neurological conditions e.g. Parkinson's Disease, autonomic neuropathy etc. would be allowed)~* Magnetic Resonance Imaging (MRI) substudy in 40 DM patients only: claustrophobia and implants incompatible with 3-Tesla MRI~* Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a C-peptide of \<0.8 ng/mLd and fasting blood glucose \>150 mg/dL will be excluded even without history of hypoglycemia during finger stick measurements.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Type 2 Diabetes Mellitus - Insulin (Type: EXPERIMENTAL): 40 IU of regular human insulin once daily over 24 weeks
- Type 2 Diabetes Mellitus - Placebo (Type: PLACEBO_COMPARATOR): Intranasal sterile saline once daily over 24 weeks
- Control - Insulin (Type: EXPERIMENTAL): 40 IU of regular human insulin once daily over 24 weeks
- Control - Placebo (Type: PLACEBO_COMPARATOR): Intranasal sterile saline once daily over 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with mild to moderate acne vulgaris on the face,.~* Subjects of either sex aged between 12 and 39 years, inclusive.~* Subjects agreeing not to use sun-beds or undergo any UV light treatment for 4 weeks prior to entering the study and to minimize the amount of exposure to direct sunlight for the duration of the study.~Exclusion Criteria:~* Women who are pregnant, breast-feeding, or sexually active with the potential to have children, and not using a contraception method that is safe from a medical point of view~* Subjects using anti-androgen containing contraceptives.~* Subjects who, during the past month, have received oral or topical steroids or antibiotics, or acne treatment of any type, including natural or artificial UV therapy.~* Subjects who have a history of hypersensitivity or idiosyncratic reaction to clindamycin phosphate, benzoyl peroxide, adapalene or any components of the medicinal products which will be used during the study.~* Subjects using, or having used in the past month, any significant concomitant medicinal product which might affect their acne, as judged by the Investigator.~* Subjects with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.~* Subjects with a history of photosensitivity.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Duac Gel (Type: EXPERIMENTAL): Duac Gel
- Differin gel (Type: ACTIVE_COMPARATOR): Differin gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and who also have 3 additional cardiovascular risk factors, including dyslipidemia.~Exclusion Criteria:~* Subjects who are taking the following prohibited medications within 14 days of screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, \>3 antihypertensive agents (including Norvasc)~* Subjects that have not been on a stable dose of Norvasc for at least 4 weeks~* Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular Disease (PVD)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norvasc 5 mg (Type: ACTIVE_COMPARATOR): Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
- Caduet 10/20mg (Type: EXPERIMENTAL): Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
- Norvasc 10 mg (Type: ACTIVE_COMPARATOR): Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
- Caduet 5/20mg (Type: EXPERIMENTAL): Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Conservative Pulp Therapy of Primary Molars Using TheraCAL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Four to six years old healthy children~* Cooperative (frankle scale + and ++)~* With at least one vital and restorable primary molar with deep caries.~Exclusion Criteria:~* History of spontaneous pain, swelling, or sinus tract~* Pathological mobility~* pain on percussion~* Furcation or periapical radiolucency~* Internal or external pathological root resorption~* Widening of periodontal membrane space~* Discontinuity of lamina dura.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- indirect pulp capping (Type: EXPERIMENTAL): TheraCAL PT will be applied to affected dentin covering the pup.
- Direct pulp Capping (Type: EXPERIMENTAL): TheraCAL PT will be applied to pinpoint pulp exposures surrounded by sound dentin.
- Partial Pulpotomy (Type: EXPERIMENTAL): Pulp exposure will be enlarged to a depth of 1-3 mm by a sterile round diamond bur, and then TheraCAL PT will applied after hemostasis.
- pulpotomy (Type: EXPERIMENTAL): complete removal of coronal pulp tissue will be attempted if bleeding persisted after attempting Partial pulpotomy for exposures that are not eligible for DPC. TheraCAL PT will be applied thereafter, after achieving hemostasis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine vs Placebo in the Treatment of General Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients at least 18 years of age presenting with generalized anxiety disorder (GAD) based on the disease diagnostic criteria The patient must suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise specified (NOS). Symptoms of GAD should not be situational in nature.~* Females of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who are not breastfeeding; test negative for pregnancy at the time of enrollment based on a urine pregnancy test; and agree to use a reliable method of birth control during the study and for 1 week following the last dose of study drug.~* Must have a Clinical Global Impressions of Severity (CGI-Severity) score of greater than or equal to 4 at Visit 1 and Visit 2.~* At Visit 1, patient must have a Covi Anxiety Scale (CAS) score of greater than or equal to 9, no item in the Raskin Depression Scale (RDS) may be greater than 3, and the CAS must be greater than the RDS.~* Must have a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of greater than or equal to 10 at Visit 1.~Exclusion Criteria:~* Any current and primary DSM-IV Axis I diagnosis other than GAD.~  * Patients diagnosed with or who have a history of major depressive disorder (MDD) within the past 6 months or~ * Patients diagnosed with or who have a history of Panic Disorder, Post-Traumatic Stress Disorder (PTSD), or an eating disorder within the past year or~ * Patients who have been diagnosed with Obsessive Compulsive Disorder (OCD), Bipolar Affective Disorder, psychosis, factitious disorder, or somatoform disorders during their lifetime.~* The presence of an Axis II disorder or history of antisocial behavior, which, in the judgment of the investigator, would interfere with compliance with the study protocol.~* Benzodiazepine use 14 days prior to Visit 2.~* Patients judged clinically to be at serious suicidal risk, or patients who, in the opinion of the investigator, are poor medical or psychiatric risks for study completion.~* Have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. male or female patient 35-65 years of age with an unilateral OAH requiring a THA and a healthy contralateral hip~2. body weight ≤110 kg or body mass index (BMI) ≤35 kg/m2~3. living in the Uppsala County~4. the eligible patients should have been given oral information, a written Patient Information and signed an Informed Consent~Exclusion Criteria:~1. on or previously have had bone-specific treatment, e.g. bisphosphonates, raloxifene, parathyroid hormone, strontium ranelate, during the last five years~2. patients on systemical corticosteroid for more than 3 months should not be considered~3. patients with diagnosed malignant disease during the last five years or known to have metastasis from malignant disease should be excluded~4. patients with compromised general conditions and an American Society of Anesthesiologists, ASA-score \>31 should not be regarded eligible~5. patients with known drug or alcohol abuse or regarded as socially dysfunctional, as judged by the investigator, should not be considered for the study~6. pregnant women or women planning for pregnancy or fertile women (premenopausal) without contraceptives should not be accepted for the study~7. patients that have been exposed frequently and/or have had large irradiation doses, as judged by the investigator, must not be included in the study.~8. enrolled in either another investigational drug study, in another investigational device study, or in another investigational study of an approved drug within 30 days prior to Visit 1 of the current study~9. any condition or laboratory findings which in the opinion of the Investigator makes the patient unsuitable for inclusion (for example claustrophobia)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): 1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
- saline (Type: PLACEBO_COMPARATOR): 1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empowering Latinas to Obtain Breast Cancer Screenings

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 52-75 years old;~* Identification as Latina/Hispanic/Chicana female;~* Residence in Pilsen, Little Village, East Side or South Chicago;~* No history of health volunteerism;~* No history of breast cancer; and~* Lack of a mammogram within the last two years~Exclusion Criteria:~* Not meeting all inclusion criteria;~* Women will be excluded if they participated in formative focus groups

- Gender: FEMALE
- Minimum Age: 52 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Empowerment (Type: EXPERIMENTAL): Behavior: Empowerment
- Education (Type: EXPERIMENTAL): Behavior: Education

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis.~* The patient is willing to take nothing by mouth including inhaled treatments except trial medication during the two hours while at the site and following trial drug administration (e.g. not smoking, food, drink, candy, lozenges, chewing gum). The patient will be allowed food and drink between hours 2 and 24, but no other oral or inhaled treatments such as smoking, lozenges, chewing gum. After the two hour assessment, the patients will be allowed food and drink within one half-hour following any hourly evaluations sore throat.~Exclusion Criteria:~* The patient has used any analgesic/antipyretic within 1 dosing interval preceding administration of the first dose of trial medication.~* The patient anticipates using any inhaled therapy including beta-agonists (e.g., ventolin) during the 24 hour trial period and, if used, has only used inhaled therapy on an intermittent basis in the week prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- celecoxib 50 mg/50 mg (Type: EXPERIMENTAL): None
- celecoxib 100 mg/placebo (Type: EXPERIMENTAL): None
- celecoxib 100 mg/50 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete